Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference By: Shattuck Labs, Inc. via GlobeNewswire January 04, 2024 at 16:05 PM EST AUSTIN, TX and DURHAM, NC, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will present a corporate update and participate in one-on-one meetings at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8-11, 2024. Presentation DetailsConference: 42nd Annual J.P. Morgan Healthcare ConferencePresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: Thursday, January 11, 2024Time: 12:00 p.m. PT Location: Westin St. Francis, San Francisco, CA A live webcast of the presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date. About Shattuck Labs, Inc.Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, (“ARC®”), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. Investor & Media Contact: Conor RichardsonVice President of Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference By: Shattuck Labs, Inc. via GlobeNewswire January 04, 2024 at 16:05 PM EST AUSTIN, TX and DURHAM, NC, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will present a corporate update and participate in one-on-one meetings at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8-11, 2024. Presentation DetailsConference: 42nd Annual J.P. Morgan Healthcare ConferencePresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: Thursday, January 11, 2024Time: 12:00 p.m. PT Location: Westin St. Francis, San Francisco, CA A live webcast of the presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date. About Shattuck Labs, Inc.Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, (“ARC®”), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. Investor & Media Contact: Conor RichardsonVice President of Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com
AUSTIN, TX and DURHAM, NC, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will present a corporate update and participate in one-on-one meetings at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8-11, 2024. Presentation DetailsConference: 42nd Annual J.P. Morgan Healthcare ConferencePresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: Thursday, January 11, 2024Time: 12:00 p.m. PT Location: Westin St. Francis, San Francisco, CA A live webcast of the presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date. About Shattuck Labs, Inc.Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, (“ARC®”), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. Investor & Media Contact: Conor RichardsonVice President of Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com